Finance

Beta
Lists
CONCORDBIO:NSE
Concord Biotech Ltd
â‚ą1,193.90
-1.32%
(-16.00) 1D
Jun 8, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for CONCORDBIO...
Open
â‚ą1,204.10
High
â‚ą1,230.90
Low
â‚ą1,190.00
Mkt. cap
124.90B
Avg. vol.
466.63K
Volume
163.63K
Dividend
0.63%
Quarterly dividend
â‚ą1.89
Ex-dividend date
Jul 24, 2026
P/E ratio
48.18
52-wk high
â‚ą2,150.40
52-wk low
â‚ą987.00
EPS
â‚ą24.78
No. of employees
2K
Open
â‚ą1,204.10
High
â‚ą1,230.90
Low
â‚ą1,190.00
Mkt. cap
124.90B
Avg. vol.
466.63K
Volume
163.63K
Dividend
0.63%
Quarterly dividend
â‚ą1.89
Ex-dividend date
Jul 24, 2026
P/E ratio
48.18
52-wk high
â‚ą2,150.40
52-wk low
â‚ą987.00
EPS
â‚ą24.78
No. of employees
2K
News stories
From sources across the web
Profile
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients sold worldwide. It manufactures biopharmaceutical products across therapy segments such as immunosuppressant, oncology, antifungal, antibacterial and anthelmintic. It has two manufacturing facilities–at Dholka near Ahmedabad, which is approved by USFDA, and at Limbasi in Kheda district. Wikipedia
About Concord Biotech Ltd
CEO-
Employees1.57K
Founded2000
Headquarters-
SectorPharmaceutical industry
Websiteconcordbiotech.com
Last report
Jun 1, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
â‚ą8.46 / â‚ą8.90
-4.94%miss
Revenue / Est. (INR)
3.26B / 3.74B
-12.71%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.04B
2.47B
2.78B
3.26B
Cost of goods sold
745.80M
775.44M
941.71M
1.16B
Cost of revenue
745.80M
775.44M
941.71M
1.16B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
378.97M
444.56M
467.81M
477.71M
Operating expense
857.87M
994.14M
1.03B
1.12B
Total operating expenses
1.60B
1.77B
1.98B
2.27B
Operating income
436.20M
701.00M
802.34M
989.88M
Other non operating income
136.78M
133.52M
99.76M
153.50M
EBT including unusual items
587.32M
856.84M
861.56M
1.14B
EBT excluding unusual items
587.32M
856.84M
894.31M
1.14B
Income tax expense
146.74M
226.21M
225.14M
256.08M
Effective tax rate
24.98%
26.40%
26.13%
22.45%
Other operating expenses
301.13M
365.67M
378.34M
442.02M
Net income
440.58M
635.81M
644.77M
887.90M
Net profit margin
21.60%
25.74%
23.21%
27.23%
Earnings per share
4.21
6.03
6.31
8.46
Interest and investment income
-
-
-
-
Interest expense
-586.00K
-591.00K
-815.00K
-840.00K
Net interest expenses
-586.00K
-591.00K
-815.00K
-840.00K
Depreciation and amortization charges
177.76M
183.92M
187.47M
195.44M
EBITDA
572.14M
881.84M
933.85M
1.18B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer